AstraZeneca reveals plans to use $500m to establish a global R&D centre and its corporate headquarters in Cambridge.
Global pharmaceutical firms AstraZeneca is to invest $500m in the construction of a new global R&D centre and the relocation of its headquarters in Cambridge. The announcement comes as part of a wider company plan to establish three R&D centres in the UK, the US and Sweden to drive biopharmaceutical research. The company, which will…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
